EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a Pennsylvania-based biopharmaceutical company, announced the recent appointment of Carol A. Schafer to its Board of Directors, marking another strategic move for the company known for its targeted oncology therapeutics.
With over 25 years of experience in investment banking and equity capital markets, Schafer brings a wealth of financial expertise to the table. Her strategic insight and understanding of equity markets are expected to be pivotal as Immunome continues to expand and advance its pipeline of cancer treatments.
Clay B. Siegall, Ph.D., Chairman and CEO of Immunome, expressed his optimism about Schafer’s appointment, stating that her experience will be invaluable in developing best-in-class and first-in-class treatments for cancer patients.
Schafer responded to her appointment with equal enthusiasm, expressing admiration for Immunome’s innovative approach to developing Antibody-Drug Conjugates (ADCs) and radioligand therapies. She also expressed eagerness to collaborate with the Board of Directors and management team to advance Immunome’s ambitious pipeline and maximize its strong financial position.
Currently serving as the Managing Partner of Hyphen Advisors, Schafer’s impressive portfolio also includes directorships at Insmed, Repare Therapeutics, and Kura Oncology. Previously, she served on the Board of Directors of Five Prime Therapeutics and Idera Pharmaceuticals.
Prior to her role at Hyphen Advisors, Schafer held a key position as Vice Chair of Wells Fargo Securities. There, she led the healthcare equity capital markets team and was responsible for originating and executing equity and convertible financings. Her past roles also include Vice President of Finance and Business Development of Lexicon Pharmaceuticals and Managing Director, Equity Capital Markets of JPMorgan Chase.
Schafer’s academic credentials include an MBA from New York University and a BA in mathematics and computer science from Boston College. Her appointment to Immunome’s Board of Directors is expected to fortify the company’s strategic growth plans, especially in the development and commercialization of targeted oncology therapeutics.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.